Strategies for the treatment of dengue virus infections: a narrative account.

  • De Clercq E
  • 27

    Readers

    Mendeley users who have this article in their library.
  • 2

    Citations

    Citations of this article.

Abstract

In comparison with other virus infections, such as HIV, HBV, HCV, influenza and herpes virus, dengue virus infections have received relatively little attention from a (chemo)therapeutic viewpoint, despite their global incidence (2.5 billion people estimated to be at risk) and absence of an effective prophylactic measure (i.e., vaccination). However, the replicative cycle of the dengue virus offers a wealth of potential target sites, including virus adsorption and fusion, RNA-dependent RNA polymerase (and the associated 2´-O-methyltransferase) and the N-glycosylation process. Numerous compounds have been identified that interfere with dengue virus infections (i.e., ribavirin, interferon, sulfated polysaccharides, 2´-C-methylnucleoside analogs and iminosugar derivatives). For other compounds found to be effective against the dengue virus, including geneticin (G418) and FGI-106, the mechanism of action still remains unresolved.

Author-supplied keywords

  • Animals
  • Antiviral Agents
  • Antiviral Agents: chemistry
  • Antiviral Agents: pharmacology
  • Antiviral Agents: therapeutic use
  • Dengue
  • Dengue Virus
  • Dengue Virus: drug effects
  • Dengue Virus: physiology
  • Dengue: drug therapy
  • Humans
  • Molecular Structure
  • RNA Replicase
  • RNA Replicase: metabolism
  • Virus Replication
  • Virus Replication: drug effects

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Erik De Clercq

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free